Literature DB >> 8633917

Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma.

C H Su1, S H Tsay, C C Wu, Y M Shyr, K L King, C H Lee, W Y Lui, T J Liu, F K P'eng.   

Abstract

UNLABELLED: OBJECTIVE; Morbidity and mortality involved in the resection of hilar cholangiocarcinoma were reviewed retrospectively. The clinicopathologic and laboratory parameters that might influence the patient's survival also were re-evaluated. SUMMARY BACKGROUND DATA: Although much progress has been made in the diagnosis and management of hilar cholangiocarcinoma, long-term outlook for most patients remains poor. Surgical resection is usually prohibited because of its local invasiveness, and most patients can only be managed by palliative drainage. Recently, many surgeons have adopted a more aggressive resection with varying degrees of success. Several prognostic factors in bile duct carcinoma have been proposed; however, no reports have specifically focused on resected hilar cholangiocarcinoma and its prognostic survival factors using multivariate analysis.
METHODS: The clinical records and pathologic slides of 49 cases with resected hilar cholangiocarcinoma were reviewed retrospectively. Twenty clinical and laboratory parameters were evaluated for their correlation with postoperative morbidity and mortality, whereas 31 variables were evaluated for their significance with postoperative survival. Variables showing statistical significance in the first univariate analysis were included in the following multivariate analysis using stepwise logistic regression test for factors affecting morbidity and mortality and Cox stepwise proportional hazard model for factors influencing survival.
RESULTS: There were 5 in-hospital deaths, and the cumulative 5-year survival rate in 44 patients who survived was 14.9%, with a median survival of 14.0 months. Multivariate analysis disclosed that co-existent hepatolithiasis and lower serum asparate aminotransferase levels (<90 U/L) had a significant low incidence of postoperative morbidity, whereas a serum albumin of less than 3 g/dL was the only significant factor affecting mortality. Regarding survival, univariate analysis identified eight significant factors: 1) total bilirubin > or = 10 mg/dL, 2) curative resection, 3) histologic type, 4) perineural invasion, 5) liver invasion, 6) depth of cancer invasion, 7) positive proximal resected margin, and 8) positive surgical margin. However, multivariate analysis disclosed total bilirubin > or = 10 mg/dL, curative resection, and histologic type as the three most significant independent variables.
CONCLUSIONS: Surgical resection provides the best survival for hilar cholangiocarcinoma. An adequate nutritional support to increase serum albumin over 3 g/dL is the most important factor to decrease postoperative mortality. Moreover, preoperative biliary drainage to decrease jaundice and a curative resection with adequate surgical margin are recommended if longer survival is anticipated. Patients with well-differentiated adenocarcinoma seem to survive longer compared to those with moderately or poorly differentiated tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8633917      PMCID: PMC1235134          DOI: 10.1097/00000658-199604000-00007

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  42 in total

1.  Twelve years' experience with transhepatic intubation.

Authors:  R C Praderi
Journal:  Ann Surg       Date:  1974-06       Impact factor: 12.969

2.  Hepaticojejunostomy. Modified longmire operation for bile duct carcinoma.

Authors:  R C Sullivan; T D Faris
Journal:  Am J Surg       Date:  1967-11       Impact factor: 2.565

3.  Intrahepatic cholangiojejunostomy in the management of malignant biliary obstruction.

Authors:  H Ragins; A Diamond; C H Meng
Journal:  Surg Gynecol Obstet       Date:  1973-01

4.  Radical resection and liver grafting as the two main components of surgical strategy in the treatment of proximal bile duct cancer.

Authors:  R Pichlmayr; B Ringe; W Lauchart; W O Bechstein; G Gubernatis; E Wagner
Journal:  World J Surg       Date:  1988-02       Impact factor: 3.352

5.  Carcinoma of the hepatic hilus. Surgical management and the case for resection.

Authors:  B Launois; J P Campion; P Brissot; M Gosselin
Journal:  Ann Surg       Date:  1979-08       Impact factor: 12.969

6.  Percutaneous transhepatic drainage of the biliary tract: technique and results in 104 cases.

Authors:  T Nakayama; A Ikeda; K Okuda
Journal:  Gastroenterology       Date:  1978-03       Impact factor: 22.682

7.  Evaluation of aggressive surgery for carcinoma of the extrahepatic bile ducts.

Authors:  A Evander; P Fredlund; J Hoevels; I Ihse; S Bengmark
Journal:  Ann Surg       Date:  1980-01       Impact factor: 12.969

8.  Surgical treatment of adenocarcinoma. Location: junction of the right, left, and common hepatic biliary ducts.

Authors:  O E Akwari; K A Kelly
Journal:  Arch Surg       Date:  1979-01

9.  Considerations that lower pancreatoduodenectomy mortality.

Authors:  J W Braasch; B N Gray
Journal:  Am J Surg       Date:  1977-04       Impact factor: 2.565

Review 10.  Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma: a study of 57 autopsy-proven cases.

Authors:  K Okuda; Y Kubo; N Okazaki; T Arishima; M Hashimoto
Journal:  Cancer       Date:  1977-01       Impact factor: 6.860

View more
  94 in total

1.  Management of hilar cholangiocarcinoma: comparison of an American and a Japanese experience.

Authors:  J I Tsao; Y Nimura; J Kamiya; N Hayakawa; S Kondo; M Nagino; M Miyachi; M Kanai; K Uesaka; K Oda; R L Rossi; J W Braasch; J M Dugan
Journal:  Ann Surg       Date:  2000-08       Impact factor: 12.969

Review 2.  Liver resection for cancer.

Authors:  R W Parks; O J Garden
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

3.  Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.

Authors:  W R Jarnagin; Y Fong; R P DeMatteo; M Gonen; E C Burke; J Bodniewicz BS; M Youssef BA; D Klimstra; L H Blumgart
Journal:  Ann Surg       Date:  2001-10       Impact factor: 12.969

Review 4.  Photodynamic therapy in the biliary tract.

Authors:  M Ortner
Journal:  Curr Gastroenterol Rep       Date:  2001-04

Review 5.  Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer.

Authors:  J R A Skipworth; S W M Olde Damink; C Imber; J Bridgewater; S P Pereira; M Malagó
Journal:  Aliment Pharmacol Ther       Date:  2011-09-20       Impact factor: 8.171

6.  Safe and permissible limits of hepatectomy in obstructive jaundice patients.

Authors:  Tetsuya Takahashi; Shinji Togo; Kuniya Tanaka; Itaru Endo; Yoshiro Fujii; Hiroshi Shimada
Journal:  World J Surg       Date:  2004-04-19       Impact factor: 3.352

Review 7.  Perineural invasion and associated pain in pancreatic cancer.

Authors:  Aditi A Bapat; Galen Hostetter; Daniel D Von Hoff; Haiyong Han
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

8.  Improved Survival in Surgically Resected Distal Cholangiocarcinoma Treated with Adjuvant Therapy: a Propensity Score Matched Analysis.

Authors:  Caitlin Hester; Ibrahim Nassour; Beverley Adams-Huet; Mathew Augustine; Michael A Choti; Rebecca M Minter; John C Mansour; Patricio M Polanco; Matthew R Porembka; Sam C Wang; Adam C Yopp
Journal:  J Gastrointest Surg       Date:  2018-07-20       Impact factor: 3.452

9.  Perineural invasion in early-stage cervical cancer and its relevance following surgery.

Authors:  Yi Zhu; Guonan Zhang; Yan Yang; Ling Cui; Shijun Jia; Yu Shi; Shuiqin Song; Shiqiang Xu
Journal:  Oncol Lett       Date:  2018-02-26       Impact factor: 2.967

10.  Spiegel's lobe bile ducts often drain into the right hepatic duct or its branches: study using drip-infusion cholangiography-computed tomography in 179 consecutive patients.

Authors:  Masahiro Kitami; Gen Murakami; Saiho Ko; Kei Takase; Masahiro Tuboi; Haruo Saito; Yoshiyuki Nakajima; Shoki Takahashi
Journal:  World J Surg       Date:  2004-09-29       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.